Search Results

Asep Medical Holdings Inc. is very pleased to announce that, through its subsidiary Sepset Biosciences Inc., it has signed a definitive joint venture agreement with leading Chinese medical diagnostic company, Sansure Biotech Inc., through its subsidiary, Hunan Xiang Jiang Sansure Biotech Fund, L.P. Sansure Fund is an investment fund formed by Sansure, Changsha Sanway Spring Venture Capital CO., Ltd. and certain other investors.

Of the 102 company launches or series A financings since October 2023, just nine had a woman at the helm, according to a BioSpace analysis. This is happening in an era of biotech where new company founders are searching for CEOs with a track record.

Back in 2023, Novo Nordisk committed up to $1.3 billion for a hypertension and kidney disease drug from KBP Biosciences. Now, the pharma giant claims to have been misled by the biotech’s founder—and a judge seems to agree.

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space dominated by Vertex.

At the J.P. Morgan Healthcare Conference, the Biotech CEO Sisterhood assembled in Union Square to showcase the large group of women and allies in biopharma as their authentic selves.

In this short teaser, BioSpace’s Head of Insights Lori Ellis talks to CBER Director Peter Marks and Tom Whitehead, Co-Founder of the Emily Whitehead Foundation about anticipated discussions at the upcoming GenScript Biotech Forum.

Orbis emerged from stealth in February 2024 with $28.1 million in seed funding. The Danish biotech, which aims to flip biologics into oral medicines, has now raised another $93 million.

The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) with Eli Lilly’s expertise in R&D—plus half a billion in capital from the Big Pharma.

QuantuMDx Group Limited, announces it has entered into a cooperation agreement with Sansure Biotech Inc., an in-vitro diagnostic solution provider based in Changsha, Hunan province, China, to accelerate the regional commercialisation of Q-POC™ and its assays, in China.

With climbing biotech M&A and IPO activity following the post-pandemic slump, experts offer insights on maximizing value and otherwise capitalizing on exit opportunities.